Log in

Industry News Archive

Live Discussion: CD38-Directed Antibody for the Treatment of RRMM

CD38-Directed Antibody for the Treatment of Appropriate Relapsed Refractory Multiple Myeloma Patients
Thursday, June 25
5:00 PM PT

Participants of this live discussion will be able to:

  • Learn about the indication, mechanism of action, and important safety information for Sarclisa (isatuximab-irfc)

  • Gain in-depth knowledge on clinical data in adult patients with relapsed refractory multiple myeloma

  • Understand the dosage and administration of Sarclisa.

  • Learn about support available for eligible patients treated with Sarclisa. 

For registration information or to learn more, click here

Posted 6/25/2020

1801 Research Boulevard Suite 400
Rockville, MD 20850
Tel: 301.984.9496 | Fax: 301.770.1949
Email Us